for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ResMed Inc.

RMD.N

Latest Trade

147.78USD

Change

0.68(+0.46%)

Volume

135,498

Today's Range

146.58

 - 

148.46

52 Week Range

90.64

 - 

149.87

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
147.10
Open
146.70
Volume
135,498
3M AVG Volume
10.93
Today's High
148.46
Today's Low
146.58
52 Week High
149.87
52 Week Low
90.64
Shares Out (MIL)
143.79
Market Cap (MIL)
21,150.94
Forward P/E
35.77
Dividend (Yield %)
1.06

Next Event

Resmed Inc Annual Shareholders Meeting

Latest Developments

More

Resmed Reports Q1 Non-GAAP EPS Of $0.93

Resmed Inc. Q4 NON-GAAP Earnings Per Share $0.95

ResMed Inc Reports Q3 Non-GAAP Earnings Per Share $0.89

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ResMed Inc.

ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.

Industry

Medical Equipment & Supplies

Contact Info

9001 Spectrum Center Blvd

+1.858.7462400

https://www.resmed.com/

Executive Leadership

Peter C. Farrell

Non-Executive Chairman of the Board

Robert Andrew Douglas

President, Chief Operating Officer

Michael J. Farrell

Chief Executive Officer, Director

Brett A. Sandercock

Chief Financial Officer

Jim R. Hollingshead

President – Sleep Business

Key Stats

2.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

2.1K

2018

2.3K

2019

2.6K

2020(E)

2.9K
EPS (USD)

2017

2.820

2018

3.530

2019

3.640

2020(E)

4.113
Price To Earnings (TTM)
50.05
Price To Sales (TTM)
7.84
Price To Book (MRQ)
9.99
Price To Cash Flow (TTM)
36.25
Total Debt To Equity (MRQ)
57.63
LT Debt To Equity (MRQ)
57.07
Return on Investment (TTM)
13.60
Return on Equity (TTM)
11.77

Latest News

Latest News

Fisher & Paykel, ResMed settle global patent disputes; shares jump

New Zealand medical device maker Fisher & Paykel Healthcare Corp Ltd and U.S. rival ResMed Inc have agreed to settle patent infringement disputes, ending a three-year tussle that spanned the globe and cost each side millions of dollars in legal fees.

NZ's Fisher & Paykel and ResMed settle global patent disputes

Medical device maker Fisher & Paykel Healthcare and U.S.-based ResMed on Thursday agreed to settle disputes over patent infringement, bringing to an end a tussle spanning the globe.

USITC to investigate Resmed for alleged patent infringement

The U.S. International Trade Commission (USITC) said on Friday it would investigate California-based Resmed Inc for a patent infringement complaint related to sleep apnea mask systems.

NZ's Fisher & Paykel Healthcare files complaint in the U.S. against Resmed

Medical device maker Fisher & Paykel Healthcare said on Tuesday it had filed a patent infringement complaint against California-based Resmed, alleging it infringed five of its patents related to sleep apnea devices.

NZ's Fisher & Paykel Healthcare files patent infringement complaint against ResMed

Medical device maker Fisher & Paykel Healthcare said on Tuesday it had filed a patent infringement complaint in the United States against ResMed .

UPDATE 1-NZ's Fisher & Paykel cuts FY guidance on ResMed-linked legal costs

New Zealand medical device firm Fisher & Paykel Healthcare Corp cut its fiscal 2019 net profit outlook on Monday on the back of expected legal costs to contest patent allegations made by ResMed Inc.

NZ's Fisher & Paykel Healthcare cuts FY guidance on higher expected legal costs

New Zealand medical device firm Fisher & Paykel Healthcare Corp cut its fiscal 2019 net profit outlook on Monday on the back of expected legal costs to contest patent allegations made by ResMed Inc.

BRIEF-Infoscan Signs LoI With ResMed Polska

* REPORTED ON WEDNESDAY IT HAS SIGNED LETTER OF INTENT (LOI) WITH RESMED POLSKA ON COOPERATION

BRIEF-Resmed Inc Q3 GAAP Earnings Per Share $0.76

* RESMED INC ANNOUNCES RESULTS FOR THE THIRD QUARTER OF FISCAL YEAR 2018

BRIEF-Resmed Says Co Entered Certain Amended And Restated Credit Agreement, Dated As Of Closing Date

* RESMED SAYS ON APRIL 17, 2018 ('CLOSING DATE'), CO ENTERED CERTAIN AMENDED AND RESTATED CREDIT AGREEMENT, DATED AS OF CLOSING DATE - SEC FILING

BRIEF-ResMed Hires Bobby Ghoshal As First Chief Technology Officer

* RESMED HIRES BOBBY GHOSHAL AS FIRST CHIEF TECHNOLOGY OFFICER Source text for Eikon: Further company coverage:

BRIEF-ResMed Q2 Gaap Earnings Per Share $0.07

* ANNOUNCES RESULTS FOR THE SECOND QUARTER OF FISCAL YEAR 2018

NZ's Fisher & Paykel sues Resmed in Australia over patent dispute

New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

NZ's Fisher & Paykel sues Resmed in patent dispute

New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

BRIEF-Resmed Inc elects Karen Drexler to its board of directors

* Resmed elects Karen Drexler to its board of directors Source text for Eikon: Further company coverage:

Fisher & Paykel says UK court rules rival Resmed's patent is invalid

New Zealand's Fisher & Paykel Healthcare said on Monday that it could continue to sell its sleep apnea masks in Britain as a UK court had ruled that rival Resmed Inc's patent was invalid.

BRIEF-Resmed updates on United Kingdom case with Fisher & Paykel​

* Ruling has no impact on Resmed's commercial operations in UK

Fisher & Paykel says UK court rules rival Resmed's patent is invalid

A British court has ruled that a patent held by health appliance firm Resmed Inc for a mask that treats sleep apnea was invalid, rival firm Fisher & Paykel Healthcare said on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up